New AHA guidelines highlight the benefits of SGLT2i medications for patients with heart failure and advances in diagnosing and treating ATTR amyloidosis.
The concept of regenerating or growing heart tissue is not far-fetched. Ongoing research by UT Southwestern may potentially change the future of care for patients with mild to moderate heart disease.
